Week in Medicine News and Research RSS Feed - Week in Medicine News and Research

TAZ represents a novel therapeutic target in NSCLC

TAZ represents a novel therapeutic target in NSCLC

Patients with non-small-cell lung cancer who express high levels of transcriptional coactivator with PDZ-binding motif may be a clinically distinct subgroup with an unfavourable prognosis, researchers report. [More]
CIP2A pathway involved in erlotinib response

CIP2A pathway involved in erlotinib response

Researchers have identified a novel mechanism, involving the cancerous inhibitor of protein phosphatase 2A pathway, which mediates the anti-tumour effects of erlotinib in non-small-cell lung cancer cells without epidermal growth factor receptor mutations. [More]
Intercalated erlotinib–eribulin ‘feasible’ without added efficacy

Intercalated erlotinib–eribulin ‘feasible’ without added efficacy

Erlotinib can be intercalated with the anti-tubule agent eribulin mesylate for patients with advanced non-small-cell lung cancer but it is unlikely to increase treatment efficacy in those without epidermal growth factor receptor activating mutations, research suggests. [More]
Third-line treatment options remain elusive for advanced, EGFR wild-type NSCLC

Third-line treatment options remain elusive for advanced, EGFR wild-type NSCLC

Phase II study findings show only marginal positive effects of third-line treatment with afatinib for advanced non-small-cell lung cancer in patients with wild-type epidermal growth-factor receptor tumour status. [More]
Six-gene signature predicts survival after targeted therapy for NSCLC

Six-gene signature predicts survival after targeted therapy for NSCLC

The presence of a six-gene profile in the microRNA of patients with advanced non-squamous non-small-cell lung cancer predicts reduced survival likelihood after first-line treatment with targeted therapy followed by chemotherapy for disease progression, indicate research results. [More]
FGFR1 amplification predicts poor outcome in early-stage NSCLC

FGFR1 amplification predicts poor outcome in early-stage NSCLC

Amplification of fibroblast growth factor receptor 1 is associated with poor clinical outcome in patients with early-stage non-small-cell lung cancer, Swiss researchers report. [More]
SCLC tumours replicated in mice from patients' CTCs

SCLC tumours replicated in mice from patients' CTCs

Scientists have used circulating tumour cells taken from patients with small-cell lung cancer to grow explant tumours in mice that retain the original’s morphological and genetic characteristics. [More]
Emphysema does not worsen lung cancer prognosis beyond pulmonary fibrosis

Emphysema does not worsen lung cancer prognosis beyond pulmonary fibrosis

Patients with combined pulmonary fibrosis and emphysema who are undergoing treatment for advanced lung cancer do not have a significantly worse prognosis than their counterparts with isolated idiopathic interstitial pneumonias, report Japanese researchers. [More]
Protein test predicts NSCLC survival benefit for chemotherapy over erlotinib

Protein test predicts NSCLC survival benefit for chemotherapy over erlotinib

Italian study results confirm that a multivariate serum protein test predicts improved survival after treatment with chemotherapy versus erlotinib for non-small-cell lung cancer, but only among patients who are likely to have a poor outcome with the latter treatment type. [More]
Survival differences after docetaxel, erlotinib are EGFR dependent

Survival differences after docetaxel, erlotinib are EGFR dependent

Results from the DELTA trial indicate no significant differences in progression-free or overall survival after treatment with docetaxel versus erlotinib in non-small-cell lung cancer patients unselected for their epidermal growth factor receptor mutation status. [More]
Erlotinib, gefitinib have similar efficacy in NSCLC patients with EGFR mutation

Erlotinib, gefitinib have similar efficacy in NSCLC patients with EGFR mutation

Disease progression-free survival is similar for patients with non-small-cell lung cancer and epidermal growth factor receptor mutations whether they receive erlotinib or gefitinib, show the results of a South Korean study. [More]
Bendamustine modestly efficacious but well tolerated in SCLC

Bendamustine modestly efficacious but well tolerated in SCLC

Patients with relapsed or treatment-resistant small-cell lung cancer can achieve modest survival benefits with few side effects when treated with bendamustine, report US researchers. [More]
Pemetrexed plus erlotinib shows benefits in NSCLC

Pemetrexed plus erlotinib shows benefits in NSCLC

Pemetrexed used in combination with erlotinib may have clinical advantage over single-agent pemetrexed when used as a second-line treatment in patients with non-squamous non-small-cell lung cancer, researchers report. [More]
IL-8 expression predicts lung adenocarcinoma prognosis

IL-8 expression predicts lung adenocarcinoma prognosis

Interleukin -8 expression is associated with a poor lung adenocarcinoma prognosis, say Japanese researchers, especially in patients whose tumours are positive for the KRAS mutation. [More]

CTR1 may be required for successful platinum-based therapy in NSCLC

Tumours with undetectable levels of the copper transporter CTR1 have a significantly reduced response to platinum-based chemotherapy for non-small-cell lung cancer, study findings indicate. [More]

Vandetanib delays disease progression in elderly NSCLC patients

Vandetanib used in combination with gemcitabine significantly improves progression-free survival compared with gemcitabine alone when used as a first-line treatment for elderly patients with advanced non-small-cell lung cancer, Italian researchers report. [More]
SUVmax predicts outcome in advanced NSCLC

SUVmax predicts outcome in advanced NSCLC

Parameters measured by positron emission tomography with integrated computed tomography at diagnosis can be used to predict outcome following concurrent chemoradiotherapy for stage III non-small-cell lung cancer, research shows. [More]

HRQoL changes predict survival in NSCLC

Changes in health-related quality of life during treatment may help predict survival in patients with advanced non-small-cell lung cancer, suggest findings from the EORTC 08975 study. [More]

CNS stimulant no more effective than placebo for alleviating lung cancer fatigue

Patients with advanced non-small-cell lung cancer who received the central nervous system stimulant modafinil reported no greater reduction in fatigue than patients given placebo, show study results. [More]

Amrubicin promise for etoposide-naïve SCLC patients

Patients with chemotherapy-refractory small-cell lung cancer may benefit from treatment with the topoisomerase II inhibitor amrubicin, research from Japan suggests. [More]